Shattuck Labs
STTK | NASDAQ
$4.66
+$0.01 (+0.22%)
At close: Nov 16, 2026, 4:00 PM ET
$4.66
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Shattuck Labs Company Profile
Company profile explainedCompany Profile
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Key Executives
| Name | Position |
|---|---|
| Taylor H. Schreiber | Co-Founder, Chief Executive Officer & Director |
| Andrew R. Neill | Chief Financial Officer |
| Abhinav A. Shukla | Chief Technical Officer |
| Arundathy Nirmalini Pandite | Chief Medical Officer |
| Brad Huckabee | Vice President of Accounting & SEC reporting |
| Casi DeYoung | Chief Business Officer |
| Kelli Collin | Senior Vice President of Quality |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer |
| Suresh de Silva | Chief Scientific Officer |
| Thomas Lampkin | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Jul 17, 2026 | SC 13D/A | [Amend] Filing |
| Jul 07, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 144 | Filing |
Shattuck Labs
| Country | United States |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Taylor H. Schreiber |
Contact Details
500 West 5th Street Austin,
Texas 78701 United States
Stock Details
| Ticker Symbol | STTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680367 |
| CUSIP Number | 82024L103 |
| ISIN Number | US82024L1035 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove STTK